Galvanize, Pfizer Consumer Healthcare work together to assist healthcare startups

Galvanize and Pfizer Consumer Healthcare (PCH) have announced a health and wellness innovation program that gives startup companies access to the Galvanize network of talent and investors. The program will seek out startups working on developing “potential solutions for improved sleep, stress management, energy, aging and nutrition.”

The first startups will be selected by Galvanize and PCH for a six-month program beginning in March. Jim Deters, Galvanize co-founder and CEO, said in a prepared statement that both companies are looking forward to assisting these startups as they work toward their goals.

“We're excited to team up with a leader in healthcare such as Pfizer Consumer Healthcare to foster innovation in the health and tech industry,” Deters said. “This program will provide an amazing environment for healthcare startups to grow and reach their full potential, and is proof of Galvanize's ability to provide great technical talent and invaluable resources for founders."

“Developing new ways for consumers to improve their health and well-being remains a priority for Pfizer Consumer Healthcare,” Suneet Varma, PCH president and general manager, said in the same statement. “Collaborating with new partners enables us to build on our own efforts to develop new, innovative ways for consumers to achieve better health and wellness by tapping into the creativity and thinking taking place all around us.”

Startups selected for the program will meet with Galvanize representatives weekly, and they will also be able to pitch their ideas to students from Galvanize’s Full Stack and Data Science programs.

Individuals interested in submitting their startup’s information for consideration have until Feb. 23. Additional information is located on Galvanize’s website

Michael Walter
Michael Walter, Managing Editor

Michael has more than 18 years of experience as a professional writer and editor. He has written at length about cardiology, radiology, artificial intelligence and other key healthcare topics.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.